TG-4050 is under clinical development by Transgene and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase I drugs for Fallopian Tube Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TG-4050’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TG-4050 is under development for the treatment of ovarian, fallopian and peritoneal serous carcinoma, head and neck cancer and head and neck cancer squamous cell carcinoma. It is administered through subcutaneous route. The drug candidate is developed based on myvac platform, modified vaccinia virus ankara (MVA) viral vector based personalized immunotherapy.
Transgene, a subsidiary of Institut Merieux SA, operates as a biotechnology company. The company offers discovery and development of immunotherapies in the areas of cancer and infectious diseases. It provides products such as therapeutic vaccines and oncolytic viruses. Transgene develops targeted immunotherapies utilizing a broad range of viral vectors. The company also concentrates on discovery of a novel approach to improve digestion of DNA impurities in the manufacturing of viral vectors. It operates through collaborations with numerous reference clinical centers, university hospitals and medical centers. It has operations in France, the US and China. Transgene is headquartered in Illkirch-Graffenstaden, Alsace, France.
For a complete picture of TG-4050’s drug-specific PTSR and LoA scores, buy the report here.